Response after single treatment with canakinumab predicts which patients will benefit most
A pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. …read more
